Literature DB >> 23791141

Author response.

Raymond W Lam.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23791141      PMCID： PMC3692727          DOI： 10.1503/jpn.130055

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  5 in total

1.  Escitalopram and QTc prolongation.

Authors:  Mehrul Hasnain; Robert H Howland; W Victor R Vieweg
Journal:  J Psychiatry Neurosci       Date:  2013-07       Impact factor: 6.186

Review 2.  Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?

Authors:  W Victor R Vieweg; Mehrul Hasnain; Robert H Howland; John M Hettema; Christopher Kogut; Mark A Wood; Ananda K Pandurangi
Journal:  Am J Med       Date:  2012-06-27       Impact factor: 4.965

3.  Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents.

Authors:  Robert D Gibbons; C Hendricks Brown; Kwan Hur; Sue M Marcus; Dulal K Bhaumik; Joëlle A Erkens; Ron M C Herings; J John Mann
Journal:  Am J Psychiatry       Date:  2007-09       Impact factor: 18.112

4.  Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults.

Authors:  Laurence Y Katz; Anita L Kozyrskyj; Heather J Prior; Murray W Enns; Brian J Cox; Jitender Sareen
Journal:  CMAJ       Date:  2008-04-08       Impact factor: 8.262

5.  Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs.

Authors:  Anne M Libby; David A Brent; Elaine H Morrato; Heather D Orton; Richard Allen; Robert J Valuck
Journal:  Am J Psychiatry       Date:  2007-06       Impact factor: 18.112
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.